Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis
Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
The aim of this multi-center, randomized, double-blind, placebo-controlled trial is to
compare the efficacy and safety of Dorithricin® lozenge - a triple combination of 0.5 mg
tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine - in repeat dosing for 3
days to matched placebo lozenges in the treatment of acute pharyngitis in adults.
Phase:
Phase 4
Details
Lead Sponsor:
Medice Arzneimittel Pütter GmbH & Co KG
Collaborators:
Milde J, Pharmalog Palm J, for the DoriPha investigators University Hospital Muenster